A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

IRB/UVA Tracking #
20474
Contact
Gracie Hockenberry
Contact Email
mgt4n@virginia.edu
Contact Phone
1.434.297.7784
Phase
III
Primary purpose
Treatment
NCT
NCT03425643
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL
Ages
Adult